The common finding in both the TCGA-AML and BeatAML cohorts was that TP53 and RUNX1 exhibited significantly higher mutation rates in the IPRP high risk group (p < 0.05, Chi-square test). This evidence concerns the gene RUNX1 and acute myeloid leukemia.